Australia markets open in 1 hour 37 minutes

Monopar Therapeutics Inc. (MNPR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.6401-0.0379 (-5.59%)
At close: 04:00PM EDT
0.6449 +0.00 (+0.75%)
After hours: 07:14PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.6780
Open0.6734
Bid0.6125 x 100
Ask0.7035 x 100
Day's range0.6216 - 0.6799
52-week range0.2740 - 1.7500
Volume33,393
Avg. volume5,413,750
Market cap11.173M
Beta (5Y monthly)1.20
PE ratio (TTM)N/A
EPS (TTM)-0.6100
Earnings date09 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.00
  • GlobeNewswire

    Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

    WILMETTE, Ill., April 18, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that its abstract on the preclinical data for its radiopharmaceutical program MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) submitted to the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting has been selected for a presentation. SNMMI 2024, held in To

  • GlobeNewswire

    Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings

    WILMETTE, Ill., April 16, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that it has filed a provisional patent application pertaining to the recent advancements and optimizations Monopar has achieved with its MNPR-101 radiopharmaceutical program. The provisional patent titled “Antibody Radioisotope Constructs” that was filed with the United States Paten

  • GlobeNewswire

    Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

    WILMETTE, Ill., April 10, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that its Phase 1 dosimetry clinical trial for its novel radiopharmaceutical imaging agent MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) is now active and recruiting patients with advanced cancers. The antibody MNPR-101 targets the urokinase plasminogen activator receptor (uPAR),